Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Imugene
Deal Size : Undisclosed
Deal Type : Agreement
Imugene and Kincell Announce Strategic Manufacturing and Process Development Partnership
Details : Under the agreement, Kincell will manufacture Imugene’s Azer-cel (azercabtagene zapreleucel), an off-the-shelf (allogeneic) cell therapy CAR T drug, to support ongoing clinical trials.
Brand Name : PBCAR0191
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Imugene
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?